PF 6252616

Drug Profile

PF 6252616

Alternative Names: PF-06252616; PF-6252616

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Pfizer
  • Developer Kennedy Krieger Institute; Pfizer
  • Class Monoclonal antibodies
  • Mechanism of Action Myostatin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy
  • Phase I/II Limb girdle muscular dystrophies

Most Recent Events

  • 01 Oct 2016 Pfizer initiates enrolment in a phase II extension trial for Duchenne muscular dystrophy (In children, In adolescents) in USA (NCT02907619)
  • 14 Sep 2016 Pfizer plans a phase II extension trial for Duchenne muscular dystrophy (In children, In adolescents) in USA, United Kingdom, Canada and Japan (NCT02907619)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Duchenne muscular dystrophy(In volunteers) in USA (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top